Oncotelic Therapeutics Unveils Nanomedicine Platform with Significant Reduction in Gastrointestinal Drug Accumulation

Oncotelic Therapeutics Inc. has unveiled its Deciparticle nanomedicine platform, which reliably formulates diverse hydrophobic drugs into uniform, intravenous-ready nanoparticles. The platform demonstrates particular promise with Everolimus, where preclinical pharmacokinetic data show the intravenous formulation reduces gastrointestinal drug accumulation by up to 67-fold compared to oral dosing. This advancement represents a significant step forward in drug delivery technology that could transform treatment paradigms in immunology and oncology.

The company presented new data at the 2025 San Antonio Breast Cancer Symposium highlighting the platform's ability to package water-resistant drugs into smaller, uniform nanoparticles suitable for intravenous administration. According to information presented at the symposium, the Deciparticle platform shows high-level compatibility across different therapeutic categories, with all five main macrolide mTOR inhibitors forming stable, monodisperse particles. This includes temsirolimus, sirolimus, ridaforolimus, Everolimus, and umirolimus, along with the key drug tacrolimus.

The platform's ability to create cGMP-ready nanomedicine formulations positions Oncotelic Therapeutics as an emerging player in next-generation drug delivery. The modular nature of the technology allows for rapid expansion of the company's immunology and oncology pipeline. The intravenous delivery method addresses significant limitations of oral dosing, particularly for hydrophobic drugs that traditionally face bioavailability challenges and unwanted gastrointestinal effects.

These developments come as the company leverages its clinical-stage nanomedicine, Sapu Nano, to advance its therapeutic pipeline. The scalability of the nanotechnology platform suggests potential for broader application across multiple drug classes beyond the current focus on mTOR inhibitors. The reduction in gastrointestinal drug accumulation represents not only a safety improvement but also potentially enhanced therapeutic efficacy through more precise drug delivery.

The implications of this technology extend beyond individual drug formulations to potentially reshape how hydrophobic therapeutics are developed and administered. By solving formulation challenges that have limited intravenous delivery of certain drug classes, the platform opens new possibilities for drug repurposing and development. The company's progress with Everolimus specifically demonstrates how established oral medications might be re-engineered for improved safety profiles and potentially expanded indications through advanced delivery systems.